Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Acquires 12,500 Shares of Stock

Altimmune, Inc. (NASDAQ:ALT) Director Jerome Benedict Durso acquired 12,500 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was bought at an average price of $4.13 per share, with a total value of $51,625.00. Following the purchase, the director directly owned 12,500 shares of the company’s stock, valued at $51,625. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Altimmune Stock Up 6.2%

ALT opened at $4.14 on Tuesday. Altimmune, Inc. has a one year low of $2.90 and a one year high of $8.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18. The stock has a market capitalization of $431.97 million, a P/E ratio of -3.87 and a beta of -0.03. The business’s 50-day simple moving average is $4.52 and its 200-day simple moving average is $4.39.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.08. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 54.79% and a negative net margin of 419,575.00%. Analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Altimmune

Several hedge funds and other institutional investors have recently made changes to their positions in ALT. Two Sigma Investments LP raised its holdings in Altimmune by 356.6% during the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock worth $7,528,000 after purchasing an additional 1,559,562 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Altimmune by 23.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after buying an additional 1,206,514 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Altimmune by 387.7% in the 2nd quarter. Federated Hermes Inc. now owns 915,458 shares of the company’s stock valued at $3,543,000 after buying an additional 727,731 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Altimmune in the 3rd quarter valued at approximately $2,204,000. Finally, Bank of America Corp DE grew its holdings in Altimmune by 155.2% during the second quarter. Bank of America Corp DE now owns 716,019 shares of the company’s stock worth $2,771,000 after acquiring an additional 435,467 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Citizens Jmp reduced their price target on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating for the company in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 15th. Citigroup reiterated a “market outperform” rating on shares of Altimmune in a research note on Wednesday, November 12th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.83.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.